aTyr Pharma (NASDAQ:ATYR) Upgraded to “Strong-Buy” at Freedom Capital

Freedom Capital upgraded shares of aTyr Pharma (NASDAQ:ATYR) from a hold rating to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

ATYR has been the topic of several other reports. Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $25.67.

aTyr Pharma Trading Up 9.9%

NASDAQ ATYR opened at $0.53 on Wednesday. The firm has a market capitalization of $52.03 million, a P/E ratio of -0.73 and a beta of 0.66. The firm’s fifty day moving average price is $0.79 and its two-hundred day moving average price is $0.80. aTyr Pharma has a 1 year low of $0.40 and a 1 year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. On average, research analysts anticipate that aTyr Pharma will post -0.66 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

A number of hedge funds have recently bought and sold shares of ATYR. Profund Advisors LLC bought a new position in aTyr Pharma during the third quarter worth about $27,000. California State Teachers Retirement System bought a new position in aTyr Pharma during the second quarter worth about $28,000. Renaissance Technologies LLC bought a new position in aTyr Pharma during the first quarter worth about $32,000. ADAR1 Capital Management LLC increased its position in aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares during the period. Finally, Kingswood Wealth Advisors LLC bought a new position in aTyr Pharma during the fourth quarter worth about $41,000. 61.72% of the stock is owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.